Detail akcie Oculis Holding Rg online

Business Summary: Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Oculis Holding AG revenues was not reported. Net loss increased from SF12.9M to SF36.9M. Higher net loss reflects clinical-stage biopharmaceutical company segment loss increase from SF10.7M to SF37.8M. Basic Earnings per Share excluding Extraordinary Items decreased from -SF0.38 to -SF0.95.